Michail_Petrov-96/iStock via Getty Images Cardiol Therapeutics ( NASDAQ: CRDL ) traded sharply lower on Thursday after announcing data from a Phase 2 trial for its lead asset, CardiolRx, in patients with recurrent pericarditis. Citing topline data from its open-label MAvERIC-Pilot study, the Canadian pharma said CardiolRx, a cannabidiol oral solution, led to a significant decline in pericarditis pain, the trial's main efficacy goal. According to the company, data suggested that in terms of a clinical measure called the 11-point numerical rating scale, the patient-reported pericardial pain declined 3.
7 points on average after eight weeks of CardiolRx from 5.8 at the baseline. The treatment was found to be safe and generally well-tolerated, Cardiol ( CRDL ) noted, adding that trial data supported the late-stage development of CardiolRx.
The U.S.-based trial enrolled 27 adults with symptomatic recurrent pericarditis.
The inflammatory disorder characterized by conditions such as pain and other symptoms has only one FDA-approved therapy, which remains costly and comes as a third-line intervention. More on Cardiol Therapeutics Seeking Alpha’s Quant Rating on Cardiol Therapeutics Historical earnings data for Cardiol Therapeutics Financial information for Cardiol Therapeutics.
